AIM: To assess the impact of a disease management programme for patients with diabetes mellitus (Type 1 and Type 2) on cost-effectiveness, quality of life and patient self-management. By organizing care in accordance with the principles of disease management, it is aimed to increase quality of care within existing budgets. METHODS: Single-group, pre-post design with 2-year follow-up in 473 patients. RESULTS: Substantial significant improvements in glycaemic control, health-related quality of life (HRQL) and patient self-management were found. No significant changes were detected in total costs of care. The probability that the disease management programme is cost-effective compared with usual care amounts to 74%, expressed in an average saving of 117 per additional life year at 5% improved HRQL. CONCLUSION: Introduction of a disease management programme for patients with diabetes is associated with improved intermediate outcomes within existing budgets. Further research should focus on long-term cost-effectiveness, including diabetic complications and mortality, in a controlled setting or by using decision-analytic modelling techniques.
AIM: To assess the impact of a disease management programme for patients with diabetes mellitus (Type 1 and Type 2) on cost-effectiveness, quality of life and patient self-management. By organizing care in accordance with the principles of disease management, it is aimed to increase quality of care within existing budgets. METHODS: Single-group, pre-post design with 2-year follow-up in 473 patients. RESULTS: Substantial significant improvements in glycaemic control, health-related quality of life (HRQL) and patient self-management were found. No significant changes were detected in total costs of care. The probability that the disease management programme is cost-effective compared with usual care amounts to 74%, expressed in an average saving of 117 per additional life year at 5% improved HRQL. CONCLUSION: Introduction of a disease management programme for patients with diabetes is associated with improved intermediate outcomes within existing budgets. Further research should focus on long-term cost-effectiveness, including diabetic complications and mortality, in a controlled setting or by using decision-analytic modelling techniques.
Authors: Ingmar Schäfer; Claudia Küver; Benjamin Gedrose; Falk Hoffmann; Barbara Russ-Thiel; Hans-Peter Brose; Hendrik van den Bussche; Hanna Kaduszkiewicz Journal: BMC Health Serv Res Date: 2010-03-03 Impact factor: 2.655
Authors: Dorijn F L Hertroijs; Arianne M J Elissen; Martijn C G J Brouwers; Nicolaas C Schaper; Sebastian Köhler; Mirela C Popa; Stylianos Asteriadis; Steven H Hendriks; Henk J Bilo; Dirk Ruwaard Journal: Diabetes Obes Metab Date: 2017-11-24 Impact factor: 6.577
Authors: Fiona Riordan; Niamh McGrath; Sean F Dinneen; Patricia M Kearney; Sheena M McHugh Journal: Int J Integr Care Date: 2019-04-03 Impact factor: 5.120
Authors: Lene Munch; Anne B Arreskov; Michael Sperling; Dorthe Overgaard; Filip K Knop; Tina Vilsbøll; Michael E Røder Journal: BMC Health Serv Res Date: 2016-04-09 Impact factor: 2.655